ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

46 hedge funds and large institutions have $219M invested in Adaptimmune Therapeutics in 2016 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 11 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

Holders
46
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$3.46M
2
+$2.79M
3
+$1.9M
4
AG
Artal Group
Luxembourg
+$1.41M
5
Renaissance Technologies
Renaissance Technologies
New York
+$983K

Top Sellers

1
-$8.6M
2
-$3.28M
3
-$2.77M
4
AC
Ascend Capital
California
-$1.16M
5
RG
Rathbones Group
United Kingdom
-$849K
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$406K
27
$388K
28
$353K
29
$208K
30
$190K
31
$178K
32
$169K
33
$164K
34
$149K
35
$113K
36
$112K
37
$94K
38
$83K
39
$70K
40
$25K
41
$23K
42
$18K
43
$11K
44
$9K
45
$7K
46
$3K
47
–
48
–
49
–
50
–
1
2
3